Efektivitas Pasca Vaksinasi Hepatitis B di Kecamatan Pakal, Surabaya, Jawa Timur
DOI:
https://doi.org/10.32662/gjph.v5i2.2461Keywords:
hepatitis B vaccine, antobody status, protection statusAbstract
Hepatitis is an infectious disease that is still a concern today and is at risk of becoming a chronic condition with complications of liver function failure. Screening is carried out to determine the level of response of the body's defense system induced by the vaccine in the population of Pakal district, Surabaya. This study assesses the relationship between antibody status and protection status after vaccination. The study involved 78 people who are eligible to receive the vaccine. After receiving the vaccine, the antibody status is checked and the data obtained were statistically tested and tested for association using a contingency coefficient. From 78 hepatitis B vaccine recipients, 69 people (88,46%) are antibody reactive and 9 people (11.54%) with non-reactive antibody status. From the Chi Square test and the contingency coefficient test, it is shown that there is a relationship between antibody status and protection status (α<0.05; 95% CI). The hepatitis B vaccine provides protection against the risk of hepatitis B virus infection for residents of the Pakal district of Surabaya who have a high-risk lifestyle.
References
Abbas, A. K., Andrew, H. and Pillai, S. 2018. Cellular and Molecular Immunology (9th ed). Philadelphia: WB Elsevier Company, pp. 87-210.
Abara WE, Qaseem A, Schillie S, et al. 2017. Hepatitis B vaccination, screening, and linkage to care: best practice advice from the American College of Physicians and the Centers for Disease Control and Prevention. Ann Intern Med.167(11):794–804.
Bruce MG, Bruden D, Hurlburt D, et al. 2016. Antibody levels and protection after hepatitis B vaccine: results of a 30-year follow-up study and response to a booster dose. J Infect Dis. 214(1):16–22.
Haile, K., Timerga, A., Mose, A., & Mekonnen, Z. 2021. Hepatitis B Vaccination Status and Associated Factors among Students of Medicine and Health Sciences in Wolkite University, Southwest Ethiopia: A cross-sectional study. PLOS ONE,16(9), e0257621.
Huether, S. E. 2014. Disorder of The Liver. In McCance, K. L., Huether, S. E. Brashers, V. L. & Rote, N.S. Pathophysiology (7th ed) Missouri: Elsevier Mosby Inc., pp. 1415-1416, 1500-1503.
Habib, A., Ayman, J., Mahmood, K., and Humma. 2014. Design and Determination of The Sample Size In Medical Research. IOSR Journal of Dental and Medical Sciences, May, 13(5 Ver. VI), pp.21-31.
Kemenkes. 2018. Hasil Utama Riskesdas tahun 2018. Jakarta : Kementerian
Kesehatan RI.
Kasper, D. L., Fauci, A. S., Hauser, S. L. et al. 2016. Harrison’s Manual of Medicine (19th ed). New York: The McGraw-Hill Companies, Inc., pp. 99-104.
Murphy, K. and Weaver, C. 2017. Janeway’s immunobiology (9th ed). New York: Garland Science, Taylor & Francis Group, LLC, pp. 139-197, 749-751.
Ocan, M., Acheng, F., Otike, C., Beinomugisha, J., Katete, D., & Obua, C. 2022. Antibody levels and protection after Hepatitis B vaccine in adult vaccinated healthcare workers in northern Uganda. PLOS ONE, 17(1), e0262126.
Sarmanu. 2019. Dasar metodologi Penelitian Kuantitatif, Kualitatif, dan Statistika. Surabaya: Airlangga University Press.
Smerdon, S.J. 2015. Protein Structure and Function. In Plopper, G., Sharp, D. and Sikorski, E. Lewin’s cell. (3rd ed). Jones & Bartlett Learning, LLC, 2015, pp. 169-228.
Weng MK, Doshani M, Khan MA, et al. 2022. Universal Hepatitis B Vaccination in Adults Aged 19–59 Years: Updated Recommendations of the Advisory Committee on Immunization Practices — United States. MMWR Morb Mortal Wkly Rep 2022;71:477–483. DOI:
http://dx.doi.org/10.15585/mmwr.mm7113a1
Wait S, Kell E, Hamid S, Muljono DH, Sollano J, Mohamed R, Shah S, Mamun-Al-Mahtab, Abbas Z, Johnston J, Tanwandee T, Wallace J. 2016. Hepatitis B and hepatitis C in southeast and southern Asia: challenges for governments. Lancet Gastroenterol Hepatol. 1(3):248-255. doi: 10.1016/S2468-1253(16)30031-0. Epub 2016 Oct 12. PMID: 28404097.
WHO. 2015. Draft global health sector strategy on viral hepatitis, 2016-2021; Geneva: World Health Organization.
